Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 7Adenocarcinoma of Lung 7Neoplasm Metastasis 4Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Melanoma 2Glioblastoma 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Liver Neoplasms 1Laryngeal Diseases 1Hepatic Impairment 1Gliosarcoma 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Bronchial Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Carboplatin 5Pemetrexed 4pembrolizumab 3osimertinib 3entinostat 3selpercatinib 2durvalumab 2camrelizumab 2Erlotinib Hydrochloride 2sotorasib 1repotrectinib 1pralsetinib 1patritumab 1napabucasin 1exemestane 1cobimetinib 1ceralasertib 1capmatinib 1alectinib 1aflutinib 1Toll-Like Receptor 1 1TNFSF10 protein, human 1Patient Reported Outcome Measures 1Paclitaxel 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bronchial Neoplasms × capmatinib × Clear all
NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Novartis

Phase 4 Completed
50 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡